Ken Griffin Pro Phase Labs, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,300 shares of PRPH stock, worth $4,305. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,300

Holding current value

$4,305

% of portfolio

0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.18 - $7.35 $12,435 - $21,866	-2,975 Reduced 43.92%	3,798 $15,000
Q1 2024 May 15, 2024	BUY	$4.47 - $6.47 $30,275 - $43,821	6,773 New	6,773 $43,000
Q3 2023 Nov 14, 2023	BUY	$4.23 - $7.53 $11,577 - $20,609	2,737 Added 511.59%	3,272 $14,000
Q2 2023 Aug 14, 2023	SELL	$7.15 - $9.78 $173,852 - $237,800	-24,315 Reduced 97.85%	535 $3,000
Q1 2023 May 15, 2023	BUY	$6.62 - $9.57 $92,388 - $133,558	13,956 Added 128.11%	24,850 $189,000
Q4 2022 Feb 14, 2023	BUY	$8.78 - $12.47 $95,649 - $135,848	10,894 New	10,894 $104,000
Q1 2022 May 16, 2022	SELL	$6.2 - $7.87 $65,242 - $82,816	-10,523 Reduced 36.99%	17,926 $125,000
Q4 2021 Feb 14, 2022	BUY	$5.13 - $7.89 $34,319 - $52,784	6,690 Added 30.75%	28,449 $203,000
Q3 2021 Nov 15, 2021	BUY	$4.89 - $7.82 $28,831 - $46,106	5,896 Added 37.17%	21,759 $113,000
Q2 2021 Aug 16, 2021	SELL	$4.61 - $6.83 $27,701 - $41,041	-6,009 Reduced 27.47%	15,863 $98,000
Q1 2021 May 17, 2021	BUY	$6.19 - $16.0 $135,387 - $349,952	21,872 New	21,872 $162,000
Q2 2019 Aug 14, 2019	SELL	$2.1 - $3.07 $36,930 - $53,989	-17,586 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.7 - $3.65 $16,310 - $22,049	6,041 Added 52.33%	17,586 $0
Q1 2018 May 11, 2018	SELL	$2.24 - $3.21 $618 - $885	-276 Reduced 2.33%	11,545 $34,000
Q4 2017 Feb 09, 2018	BUY	$2.05 - $2.3 $24,233 - $27,188	11,821	11,821 $26,000

Others Institutions Holding PRPH

# of Institutions

Shares Held

2.68M

Call Options Held

12.3K

Put Options Held

View Full List

About ProPhase Labs, Inc.

Ticker PRPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 16,024,400
Market Cap $5.61M
Description
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...

More about PRPH

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account